Table 1.

Patient characteristics (N = 54)

	Bevacizumab- naïve (N=41)	Bevacizumab-prior (N=13)
Age in years, median (range)	57 (27–79)	66 (40–72)
ECOG Performance Status, N (%)
0	2 (5%)	1 (8%)
1	39 (95%)	12 (92%)
Race/Ethnicity, N (%)
White	40 (98%)	10 (77%)
Asian	1 (2%)	2 (15%)
African American	0	1 (8%)
Hispanic	0	0
Histology
High-grade serous ovarian cancer (HGSOC)*	38 (93%)	12 (92%)
Mixed clear cell and HGSOC	2 (5%)	0
Clear cell	0	1 (8%)
Mucinous	1 (2%)	0
Platinum sensitivity+, N (%)
Platinum resistant recurrent disease	34 (83%)	13 (100%)
Platinum sensitive recurrent disease	7 (17%)	0
Median number of prior systemic treatment regiments (range)++	5 (2–9)	6 (5–9)
Prior bevacizumab treatment, N (%)	N/A
Upfront setting only		0
Upfront and recurrent settings		1
Recurrent settings only		12
Bevacizumab monotherapy		0
Both bevacizumab monotherapy and in combination**		4
Bevacizumab in combination with chemotherapy***/a PKC inhibitor		8/1
The number of use of bevacizumab-containing regimens prior to enrollment	N/A
1		5
2		4
3		4
The last dose of bevacizumab prior to study entry	N/A
≤ 6 months		6
> 6 months		7

⁺Platinum sensitive: recurs 6 or more months after cessation of platinum-based chemotherapy; platinum resistant: progression within 6 months of platinum-based therapy

^*HGSOC includes epithelial ovarian, fallopian tubal and primary peritoneal cancers.

⁺⁺Four patients received a PARP inhibitor olaparib in combination with carboplatin through a clinical trial (NCT01445418).

^**Two separate courses of therapy

^***Chemotherapy combination includes gemcitabine, taxotere, vinorelbine, capecitabine plus oxaliplatin, abraxane, carboplatin, doxorubicin, carboplatin plus taxotere, carboplatin plus doxorubicin, carboplatin plus taxol, carboplatin (or cisplatin) plus gemcitabine, cyclophosphamide, enzastaurin.

Abbreviations: N/A; not applicable